Health Catalyst has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company expects to price its 6.0 million shares in the range of $20 to $23, with an overallotment option for an additional 900,000 shares. At the maximum price, the entire offering is valued up to $158.7 million. The company intends to list its share on the Nasdaq under the symbol HCAT.
The underwriters for the offering are Goldman Sachs, JPMorgan, William Blair, Piper Jaffray, Evercore ISI, SVB Leerink and SunTrust Robinson Humphrey.
This firm is a leading provider of data and analytics technology and services to health care organizations. Its solution comprises a cloud-based data platform, analytics software and professional services expertise.
The customers are primarily health care providers, and they use Health Catalyst’s solution to manage their data, derive analytical insights to operate their organization and produce measurable clinical, financial and operational improvements.
Health Catalyst detailed its finances in the filing as follows:
For the years ended December 31, 2017 and 2018, and for the three months ended March 31, 2018 and 2019, our total revenue was $73.1 million, $112.6 million, $20.6 million, and $35.2 million, respectively. For the years ended December 31, 2017 and 2018, and for the three months ended March 31, 2018 and 2019, we incurred net losses of $47.0 million, $62.0 million, $12.2 million, and $13.7 million, respectively. For the years ended December 31, 2017 and 2018, and for the three months ended March 31, 2018 and 2019, our Adjusted EBITDA was $(35.4) million, $(38.1) million, $(9.3) million, and $(6.7) million, respectively.
The company intends to use the net proceeds from this offering for working capital and other general corporate purposes.